Amphastar Pharma (AMPH) Tops Q2 EPS by 28c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.91, $0.28 better than the analyst estimate of $0.63. Revenue for the quarter came in at $183.9 million versus the consensus estimate of $179.71 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
• Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results